Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Henan Taloph Pharmaceutical Stock Co's selling, general, & admin. expense for the
three
months ended in Jun. 2026 was ¥-11 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2026 was ¥106 Mil.
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Henan Taloph Pharmaceutical Stock Co Selling, General, & Admin. Expense Related Terms
Henan Taloph Pharmaceutical Stock Co Selling, General, & Admin. Expense Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Henan Taloph Pharmaceutical Stock Co Selling, General, & Admin. Expense Chart
SHSE:600222 vs ZTS: Selling, General, & Admin. Expense Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Henan Taloph Pharmaceutical Stock Co Selling, General, & Admin. Expense vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's Selling, General, & Admin. Expense falls into.
Henan Taloph Pharmaceutical Stock Co Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥106 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of ¥106 Mil mean?
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a Selling, General, & Admin. Expense of ¥106 Mil as of Jun. 2026. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors.
Is Henan Taloph Pharmaceutical Stock Co's Selling, General, & Admin. Expense too high?
Henan Taloph Pharmaceutical Stock Co's current Selling, General, & Admin. Expense is ¥106 Mil. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's Selling, General, & Admin. Expense compare to ZTS?
Henan Taloph Pharmaceutical Stock Co's Selling, General, & Admin. Expense of ¥106 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. Henan Taloph Pharmaceutical Stock Co's current Selling, General, & Admin. Expense is ¥106 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.96, compared to a current price of ¥8.61 — trading 73.6% above its estimated fair value. The current Selling, General, & Admin. Expense is ¥106 Mil. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current Selling, General, & Admin. Expense is ¥106 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued.
The current stock price of ¥8.61 is trading 73.6% above its estimated GF Value™ of ¥4.96.
GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.
Key valuation signals for SHSE:600222:
Selling, General, & Admin. Expense: ¥106 Mil
GF Value™: ¥4.96 vs. price of ¥8.61 (73.6% above fair value)
No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
62GF Score
Get the complete analysis for SHSE:600222
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600222 has been successfully added to your 
